1、公司名称：浙江亚太药业股份有限公司 2、统一社会信用代码：91330000146008822C 3、企业类型：其他股份有限公司（上市） 证券代码：002370 证券简称：亚太药业 公告编号：2026-015 浙江亚太药业股份有限公司 关于公司完成工商变更登记的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 浙江亚太药业股份有限公司（以下简称"公司"）于 2026 年 2 月 9 日召开的第八届董事会第十次会议审议通过了《关于聘任公司总 经理的议案》，公司董事会同意聘任邱中勋先生为公司总经理，根据 《公司章程》相关规定，总经理为公司的法定代表人，董事会聘任邱 中勋先生为公司总经理后，邱中勋先生将担任公司法定代表人，董事 会授权公司经营管理层办理工商变更登记等相关事宜，具体内容详见 2026 年 2 月 10 日公司在指定信息披露媒体《证券时报》和巨潮资讯 网（www.cninfo.com.cn）上刊载的《关于第八届董事会第十次会议 决议的公告》《关于总经理、董事会秘书、财务总监辞职暨聘任总经 理、董事会秘书、财务总监的公告》等相关公告。 近日，公司已完 ...

本公司及董事会全体成员保证公告内容真实、准确和完整，不 存在虚假记载、误导性陈述或者重大遗漏。 证券代码：002370 证券简称：亚太药业 公告编号：2026-016 浙江亚太药业股份有限公司 关于公司参与国家组织集采药品协议期满品种接续采购 拟中选的公告 | | | 适用于敏感病原菌所致的下列感染：（1）社区获得性肺炎：由肺炎衣原体、 | | --- | --- | --- | | | | 流感嗜血杆菌、嗜肺军团菌、卡他莫拉菌、肺炎支原体、金黄色葡萄球菌 | | 4 | 注射用阿奇霉素 | 或肺炎链球菌等病原菌所致，且起始治疗需静脉给药的患者；（2）盆腔炎 | | | | 性疾病：由沙眼衣原体、淋病奈瑟氏球菌或人型支原体所致，且起始治疗 | | | | 需静脉给药的患者。 | | | | 奥美拉唑钠为质子泵抑制剂，主要适用于：（1）消化性溃疡出血、吻合口 | | | | 溃疡出血；（2）应激状态时并发的急性胃黏膜损害，非甾体类抗炎药引起 | | 5 | 注射用奥美拉唑钠 | 的急性胃黏膜损伤；（3）预防重症疾病（如脑出血、严重创伤等）应激状 | | | | 态及胃手术后引起的上消化道出血等；（4）作为当口服 ...

Core Viewpoint - The company, Asia-Pacific Pharmaceutical (002370.SZ), has participated in the continuation procurement organized by the National Organization for Drug Procurement, with 13 products, including injectable Cefmetazole Sodium and Febuxostat tablets, proposed for selection in the continuation procurement process [1] Group 1: Procurement Details - The continuation procurement involves products from the first to eighth batches of the national organized procurement agreements that have expired [1] - The agreed procurement volume for each product will be based on the demand reported by medical institutions, with the selection price gradient determining the volume ratio [1] Group 2: Market Impact - Medical institutions will prioritize the use of the selected drugs from this continuation procurement during the procurement period, ensuring the completion of the agreed procurement volume [1] - If the company signs procurement contracts and implements them, it will further expand the sales of related products, enhance market share, and improve brand influence, positively impacting future operating performance [1]

Group 1 - Baichuan Co., Ltd. announced a recent price increase for some of its main products due to market supply and demand factors, but the sustainability of this price fluctuation remains uncertain, making it difficult to predict the impact on the company's performance [1] - Jincheng Co., Ltd. plans to increase its acquisition of CMH Company by an additional 42.50% stake, which will give it a total ownership of 97.5% and ultimate control over CMH [2] - Xinhang New Materials intends to raise no more than 1 billion yuan through a private placement of A-shares, with the funds allocated for projects including high-performance resin production and a composite materials innovation center [3] Group 2 - SMIC reported a sales revenue of $2.489 billion for Q4 2025, a 4.5% increase quarter-on-quarter, with an annual revenue of $9.327 billion, reflecting a 16.2% year-on-year growth [4] - China Railway Construction recently won 10 major projects, each valued over 1.5 billion yuan, totaling 45.142 billion yuan, which represents 4.23% of the company's audited revenue for 2024 [5] - Shenzhen Airport recorded a passenger throughput of 5.8795 million in January 2026, a year-on-year increase of 2.84% [6] Group 3 - China State Construction reported a new contract total of 399.5 billion yuan in January 2026, marking a 1.8% year-on-year increase [7] - Jindi Group's sales amount in January 2026 decreased by 45.78% year-on-year, with a signed area of 78,000 square meters [8] - Changyuan Power achieved a power generation of 3.971 billion kWh in January 2026, a year-on-year increase of 37.81% [9] Group 4 - Senyuan Electric is expected to win a project from the Southern Power Grid valued at 272 million yuan [10] - Chengyi Pharmaceutical's products are set to be selected for the national centralized procurement of expiring varieties [12] - Xinwufeng reported a 10.71% year-on-year decrease in pig sales volume in January 2026 [13] Group 5 - Shengnong Development's sales revenue in January 2026 increased by 40.48% year-on-year, with chicken sales volume rising by 42.79% [14] - Minglida announced the termination of its investment in a key component manufacturing project due to global economic uncertainties [15] - CITIC Securities reported that its subsidiary, Huaxia Fund, achieved a net profit of 2.396 billion yuan in 2025 [16] Group 6 - Pianzaihuang completed the first subject enrollment for its Phase II clinical trial of PZH2107 [17] - Xinzhou Bang reported a 16.56% year-on-year increase in net profit for 2025 [18] - Ankai Bus produced 761 vehicles in January 2026, a year-on-year increase of 35.65% [19] Group 7 - Weilan Bio plans to acquire a 50% stake in Aidimeng Weilan for 47 million yuan [20] - Ningbo Gaofa intends to establish a wholly-owned subsidiary with an investment of no more than 100 million yuan [21] - Shanghai Airport signed a leasing contract worth approximately 585 million yuan with the Shanghai Airport Group [22] Group 8 - Fosun Pharma's subsidiary received acceptance for a drug registration application [23] - Jindai Home's subsidiary invested in acquiring shares in a North American market company [24] - Huatong Co. reported a 1.45% year-on-year decrease in pig sales revenue in January 2026 [25] Group 9 - Yunnan Energy Investment's Nanchong Wind Power Project has been approved with a total installed capacity of 62,500 kW [28] - Youyan Silicon reported a 10.14% year-on-year decrease in net profit for 2025 [29] - Jinpu Titanium announced a temporary shutdown of its Nanjing Titanium White production due to reduced demand [30] Group 10 - Yipin Hong completed the sale of its stake in Arthrosi for a total of $9.5 billion in upfront payments [31] - Liande Co. stated that its gas turbine business currently has limited supply, with minimal impact on overall performance [32] - Tiens Wind Power signed new contracts worth 870 million yuan in the offshore engineering sector [33] Group 11 - Daqin Railway reported a freight volume of 31.28 million tons in January 2026, a year-on-year increase of 5% [34] - ST Mingcheng successfully dismissed all claims from Beijing Fusheng in a recent court ruling [35] - Zhiyang Innovation is planning to acquire control of Lingming Photon and will continue its stock suspension for up to five trading days [36][37] Group 12 - Fulai New Materials accelerated the commercialization of flexible sensors, preparing for mass production of its third-generation electronic skin products [38] - Minhe Co. reported a 36.89% year-on-year decrease in sales of broiler chicks in January 2026 [39] - Ruiang Gene received government subsidies totaling 2 million yuan [40] Group 13 - Huiyu Pharmaceutical's shareholder was forced to reduce holdings by 0.307% due to a court order [41] - Fuyuan Pharmaceutical's subsidiary obtained a drug registration certificate for a new oral solution [42] - Xuantai Pharmaceutical's product is set to be selected for national procurement [43] Group 14 - Chunqiu Electronics completed the cancellation of 9.1369 million repurchased shares [44] - Jinguang Electric won a bid worth approximately 28.8691 million yuan [45] - Hongda Co. plans to invest approximately 71.43 million yuan in a 110kV power transmission project [46] Group 15 - Nanchao Foods reported a 1.99% year-on-year decrease in revenue for January 2026 [47] - Shisheng Intelligent plans to repurchase shares worth between 17.5 million and 35 million yuan [48]

Core Viewpoint - Asia-Pacific Pharmaceutical (002370.SZ) plans to establish a wholly-owned subsidiary, Zhejiang Yatai Lizhong Investment Holding Co., Ltd., with a capital of 50 million yuan to enhance its industrial development layout [1] Group 1 - The company aims to improve its strategic development and operational planning through this investment [1] - The subsidiary's name is provisional and will be finalized upon approval from the relevant registration authority [1]

Core Viewpoint - The company plans to invest 50 million yuan to establish a wholly-owned subsidiary, Zhejiang Yatai Lizhong Investment Holding Co., Ltd., to enhance its industrial development layout and improve overall competitiveness [1] Group 1: Investment Details - The investment will be made using the company's own funds and will not affect the normal operation of its existing main business [1] - The new subsidiary will be registered in Shaoxing City, Zhejiang Province, and the establishment is subject to approval from the relevant authorities [1] - The decision to invest falls within the chairman's authority and does not require board or shareholder approval, thus not constituting a related party transaction or major asset restructuring [1] Group 2: Strategic Implications - The establishment of the subsidiary aims to promote the company's long-term sustainable development [1] - The company will actively advance the necessary registration procedures and strengthen risk management [1]

证券代码：002370 证券简称：亚太药业 公告编号：2026-014 浙江亚太药业股份有限公司 关于对外投资设立全资子公司的公告 一、对外投资概述 根据发展战略和经营规划需要，为进一步完善公司产业发展布局， 公司拟以自有资金 5,000.00 万元设立全资子公司浙江雅泰利众投资 控股有限公司（暂定名，最终以工商登记主管部门核准登记的公司名 称为准）。 根据《深圳证券交易所股票上市规则》及《公司章程》等有关规 定，公司本次对外投资事项属于董事长决策权限范围，无需提交公司 董事会及股东会审议。 本次对外投资事项不构成关联交易，也不构成《上市公司重大资 产重组管理办法》规定的重大资产重组。 二、拟设立的全资子公司基本情况 1、公司名称：浙江雅泰利众投资控股有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 浙江亚太药业股份有限公司（以下简称"亚太药业"或"公司"） 拟对外投资设立全资子公司，现将具体情况公告如下： 2、公司类型：有限责任公司 3、注册地址：浙江省绍兴市越城区沥海街道南滨西路 36 号 3 号 楼二层 4、注册资本：人民币 5,000 万元 公 ...

Core Viewpoint - Asia-Pacific Pharmaceutical (002370.SZ) announced the establishment of a wholly-owned subsidiary, Zhejiang Yatai Lizhong Investment Holding Co., Ltd., with a capital investment of 50 million yuan to enhance its industrial development layout [1] Group 1 - The company plans to use its own funds amounting to 50 million yuan for the establishment of the new subsidiary [1] - The name of the subsidiary is provisional and will be finalized upon approval from the relevant registration authority [1]

Group 1 - The company, Asia-Pacific Pharmaceutical (002370), announced a change in control, leading to the resignation of key executives including the General Manager, Secretary of the Board, and Chief Financial Officer [1] - The resignations are effective immediately upon delivery of their written resignation reports to the company's board of directors [1] - The executives who resigned, namely Cen Jianwei, Xu Wei, and Xu Jingyang, do not hold any shares in the company and have no outstanding commitments to fulfill [2]

Core Viewpoint - The control of Zhejiang Apac Pharmaceutical Co., Ltd. has changed, leading to significant management resignations and new appointments [1] Group 1: Management Changes - The board of directors received written resignation reports from Mr. Cen Jianwei (General Manager), Mr. Xu Wei (Board Secretary), and Mr. Xu Jingyang (Chief Financial Officer) [1] - The resignations are effective immediately upon delivery to the board, and the individuals will no longer hold any positions within the company [1] - Mr. Qiu Zhongxun has been appointed as the new General Manager, Mr. Zong Hao as the new Board Secretary, and Mr. Chen Xiaobiao as the new Chief Financial Officer [1] Group 2: Context of Changes - The management changes are a result of the company's control shift as per the Share Transfer Agreement and related arrangements [1] - The article highlights a trend of young executives, including a 26-year-old who recently returned from studying at a prestigious U.S. university, taking on significant roles in A-share companies [1]